


PRODUCT INFORMATION



Terazosin (hydrochloride)

Item No. 20216

CAS Registry No.: 63074-08-8
Formal Name: [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](tetrahydro-2-furanyl)-methanone, monohydrochloride
MF: $C_{19}H_{25}N_5O_4 \cdot HCl$
FW: 423.9
Purity: $\geq 98\%$
UV/Vis.: λ_{max} : 214, 247 nm
Supplied as: A crystalline solid
Storage: $-20^{\circ}C$
Stability: ≥ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Terazosin (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the terazosin (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Terazosin (hydrochloride) is soluble in the organic solvent DMSO at a concentration of approximately 0.1 mg/ml.

Description

Terazosin is a potent and selective α_1 -adrenergic receptor (α_1 -AR) antagonist (K_i s = 3.28, 0.68, and 1.09 for α_{1A} -, α_{1B} - and α_{1D} -ARs, respectively).¹ It is selective for α_1 - over α_2 -AR subtypes (K_i s = 1,510, 7.71, and 78.2 nM for A_{2a} -, A_{2b} -, and A_{2c} -ARs, respectively). Terazosin (0.1-30 mg/kg) decreases blood pressure in spontaneously hypertensive rats.² It also decreases blood pressure in anesthetized dogs. Formulations containing terazosin are used to treat hypertension and benign prostatic hyperplasia.^{3,4}

References

1. Hancock, A.A., Buckner, S.A., Ireland, L.M., *et al.* Actions of terazosin and its enantiomers at subtypes of α - and α_2 -adrenoceptors *in vitro*. *J. Recept. Signal Transduct. Res.* **15(7-8)**, 863-885 (1995).
2. Kyncl, J.J. Pharmacology of terazosin. *Am. J. Med.* **80(5B)**, 12-19 (1986).
3. Cohen, J.D. Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents. *Am. Heart J.* **122(3 Pt 2)**, 919-925 (1991).
4. Lepor, H., Williford, W.O., Barry, M.J., *et al.* The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. *N. Engl. J. Med.* **335(8)**, 533-539 (1996).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM